IL135578A0 - Compositions and methods for treating lysosomal storage disease - Google Patents

Compositions and methods for treating lysosomal storage disease

Info

Publication number
IL135578A0
IL135578A0 IL13557898A IL13557898A IL135578A0 IL 135578 A0 IL135578 A0 IL 135578A0 IL 13557898 A IL13557898 A IL 13557898A IL 13557898 A IL13557898 A IL 13557898A IL 135578 A0 IL135578 A0 IL 135578A0
Authority
IL
Israel
Prior art keywords
compositions
methods
lysosomal storage
storage disease
treating lysosomal
Prior art date
Application number
IL13557898A
Other languages
English (en)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL135578A0 publication Critical patent/IL135578A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL13557898A 1997-10-29 1998-10-29 Compositions and methods for treating lysosomal storage disease IL135578A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6352797P 1997-10-29 1997-10-29
PCT/US1998/022886 WO2000009153A1 (en) 1997-10-29 1998-10-29 Compositions and methods for treating lysosomal storage disease

Publications (1)

Publication Number Publication Date
IL135578A0 true IL135578A0 (en) 2001-05-20

Family

ID=22049811

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13557898A IL135578A0 (en) 1997-10-29 1998-10-29 Compositions and methods for treating lysosomal storage disease
IL135578A IL135578A (en) 1997-10-29 2000-04-10 Use of a vector for the manufacture of a medicament for treating gaucher disease
IL177228A IL177228A0 (en) 1997-10-29 2006-08-02 Use of a vector for the manufacture of a medicament for treating gaucher disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL135578A IL135578A (en) 1997-10-29 2000-04-10 Use of a vector for the manufacture of a medicament for treating gaucher disease
IL177228A IL177228A0 (en) 1997-10-29 2006-08-02 Use of a vector for the manufacture of a medicament for treating gaucher disease

Country Status (10)

Country Link
US (3) US6066626A (xx)
EP (2) EP1027069B1 (xx)
JP (2) JP2002522509A (xx)
AT (1) ATE333893T1 (xx)
AU (1) AU734290B2 (xx)
CA (1) CA2305768A1 (xx)
DE (1) DE69835367T2 (xx)
ES (1) ES2268799T3 (xx)
IL (3) IL135578A0 (xx)
WO (1) WO2000009153A1 (xx)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362442A (en) * 1993-07-22 1994-11-08 2920913 Canada Inc. Method for sterilizing products with gamma radiation
US20040067157A1 (en) * 1993-07-22 2004-04-08 Clearant, Inc. Methods for sterilizing biological materials
US6705323B1 (en) * 1995-06-07 2004-03-16 Conceptus, Inc. Contraceptive transcervical fallopian tube occlusion devices and methods
CA2305768A1 (en) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
AU764686B2 (en) 1998-08-28 2003-08-28 Duke University Adenoviruses deleted in the IVa2, 100K, polymerase and/or preterminal protein sequences
WO2001036603A2 (en) * 1999-11-17 2001-05-25 Avigen, Inc. Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
JP2003523330A (ja) 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
AU2001237050A1 (en) * 2000-02-17 2001-08-27 Genzyme Corporation Genetic modification of the lung as a portal for gene delivery
WO2001060377A2 (en) * 2000-02-17 2001-08-23 Genzyme Corporation Methods for treatment of lysosomal storage diseases using biphosphonates
US20040086420A1 (en) * 2000-03-23 2004-05-06 Macphee Martin J. Methods for sterilizing serum or plasma
US20040204379A1 (en) * 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP2004522763A (ja) * 2001-02-20 2004-07-29 ユーエイビー リサーチ ファンデーション リソソーム蓄積症のアミノグリコシド治療
US6682695B2 (en) * 2001-03-23 2004-01-27 Clearant, Inc. Methods for sterilizing biological materials by multiple rates
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
EP1974752B1 (en) * 2001-04-30 2012-09-26 BioMarin Pharmaceutical Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6946126B2 (en) * 2001-06-04 2005-09-20 Duke University Replicating adenovirus vectors
US6696060B2 (en) * 2001-06-14 2004-02-24 Clearant, Inc. Methods for sterilizing preparations of monoclonal immunoglobulins
US20030031584A1 (en) * 2001-08-10 2003-02-13 Wilson Burgess Methods for sterilizing biological materials using dipeptide stabilizers
US6946098B2 (en) 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US6749851B2 (en) 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes
US7252799B2 (en) * 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US20110091353A1 (en) * 2001-09-24 2011-04-21 Wilson Burgess Methods for Sterilizing Tissue
US20030095890A1 (en) * 2001-09-24 2003-05-22 Shirley Miekka Methods for sterilizing biological materials containing non-aqueous solvents
US6783968B2 (en) 2001-09-24 2004-08-31 Clearant, Inc. Methods for sterilizing preparations of glycosidases
US20030185702A1 (en) * 2002-02-01 2003-10-02 Wilson Burgess Methods for sterilizing tissue
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030124023A1 (en) * 2001-12-21 2003-07-03 Wilson Burgess Method of sterilizing heart valves
US20030180181A1 (en) * 2002-02-01 2003-09-25 Teri Greib Methods for sterilizing tissue
US7090836B2 (en) * 2002-06-21 2006-08-15 Institut Pasteur Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal
US20040013562A1 (en) * 2002-07-18 2004-01-22 Wilson Burgess Methods for sterilizing milk.
US6908591B2 (en) * 2002-07-18 2005-06-21 Clearant, Inc. Methods for sterilizing biological materials by irradiation over a temperature gradient
CN1756558B (zh) * 2003-01-31 2012-04-25 纽约大学西奈山医学院 酶和酶的活性部位特异性陪伴分子的组合
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20040258666A1 (en) * 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
EP1682504B1 (en) * 2003-11-12 2012-12-26 Amicus Therapeutics Inc. Hydroxy piperidine derivatives to treat gaucher disease
US20050244400A1 (en) * 2004-02-10 2005-11-03 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
EP1961816B1 (en) 2005-11-18 2015-09-02 Tokyo Metropolitan Institute of Medical Science Novel highly functional enzyme having modified substrate-specificity
BRPI0707590A2 (pt) 2006-02-08 2011-05-10 Genzyme Corp terapia gÊnica para a doenÇa de niemann-pick do tipo a
EP2099523A2 (en) * 2006-11-13 2009-09-16 ZyStor Therapeutics , Inc. Methods for treating pompe disease
CN101631794B (zh) 2007-01-18 2013-01-02 建新公司 包含氨基氧基基团的寡糖及其轭合物
WO2008143354A1 (ja) 2007-05-18 2008-11-27 Tokyo Metropolitan Organization For Medical Research 酵素補充療法用医薬組成物
US8252789B2 (en) 2007-11-29 2012-08-28 Neuraltus Pharmaceuticals, Inc. Compositions and methods for treating lysosomal disorders
AU2009244148B2 (en) * 2008-05-07 2014-10-09 Biomarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US20100119502A1 (en) * 2008-11-11 2010-05-13 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
CN103432566A (zh) 2008-12-16 2013-12-11 建新公司 寡糖-蛋白缀合物
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011028941A2 (en) 2009-09-04 2011-03-10 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Disabling autophagy as a treatment for lysosomal storage diseases
MX338426B (es) 2010-04-23 2016-04-15 Synageva Biopharma Corp Enzima de enfermedad del almacenamiento lisosomico.
NZ700824A (en) 2010-09-09 2016-03-31 Synageva Biopharma Corp Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
RS55405B1 (sr) 2010-11-08 2017-04-28 Amicus Therapeutics Inc Varijantni, rekombinantni proteini beta-glukocerebrozidaze sa povećanom stabilnošću i povećanom zadržanom katalitičkom aktivnošću
US20120178105A1 (en) * 2011-01-10 2012-07-12 Genzyme Corporation Detection of globotriaosylceramide (glc) in human urine samples using an antibody sandwich
WO2012112681A1 (en) 2011-02-15 2012-08-23 Shire Human Genetic Therapies, Inc. Methods for treating lysosomal acid lipase deficiency
SI2685986T1 (sl) 2011-03-18 2020-03-31 Genzyme Corporation Inhibitor glukozilceramid sintaze
JP2014513952A (ja) 2011-04-22 2014-06-19 ジェンザイム・コーポレーション 促進されたプロセシングを備えた修飾された酸性アルファグルコシダーゼ
JP6184945B2 (ja) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
ES2791760T3 (es) 2011-09-07 2020-11-05 Sinai School Medicine Ceramidasa y diferenciación celular
US9492514B2 (en) 2012-06-01 2016-11-15 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
ES2968649T3 (es) 2012-12-07 2024-05-13 Translate Bio Inc Nanopartículas lipídicas para la administración de ARNm en los pulmones
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TW202332774A (zh) 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11219695B2 (en) * 2016-10-20 2022-01-11 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of Fabry disease
WO2020046132A1 (en) 2018-08-31 2020-03-05 Leiden University Pharmacological chaperones for enzyme treatment therapy
NL2021840B1 (en) 2018-10-19 2020-05-13 Univ Leiden Pharmacological Chaperones For Enzyme Treatment Therapy
US20220001027A1 (en) * 2018-11-15 2022-01-06 President And Fellows Of Harvard College Genetically Engineered Skin Cells for the Systemic In Vivo Treatment of Deficient Enzymes, Factors or Proteins
IL288284B2 (en) 2019-05-22 2024-06-01 Massachusetts Inst Technology Circular Rana preparations and methods
CN114786710A (zh) * 2019-10-17 2022-07-22 西湖生物医药科技(杭州)有限公司 工程改造红细胞用于治疗溶酶体贮积病
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
US20240245805A1 (en) 2020-03-20 2024-07-25 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2021236855A1 (en) 2020-05-19 2021-11-25 Orna Therapeutics, Inc. Circular rna compositions and methods
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat
TW202317767A (zh) 2021-06-10 2023-05-01 美商歐納醫療公司 環狀rna組合物及方法
US20240052049A1 (en) 2022-06-24 2024-02-15 Orna Therapeutics, Inc. Circular rna encoding chimeric antigen receptors targeting bcma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5236838A (en) * 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5840710A (en) * 1994-12-09 1998-11-24 Genzyme Corporation Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
WO1997009441A2 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
US5962313A (en) * 1996-01-18 1999-10-05 Avigen, Inc. Adeno-associated virus vectors comprising a gene encoding a lyosomal enzyme
AU4352997A (en) 1996-08-30 1998-03-19 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies
AU4424497A (en) * 1996-09-13 1998-04-02 Transkaryotic Therapies, Inc. Therapy for alpha-galactosidase a deficiency
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
GB9708526D0 (en) * 1997-04-25 1997-06-18 Royal Free Hosp School Med Eukaryotic gene expression cassette and uses thereof
CA2305768A1 (en) * 1997-10-29 2000-02-24 Genzyme Corporation Compositions and methods for treating lysosomal storage disease
US5879005A (en) * 1998-02-26 1999-03-09 Baca; Ron Wargame playing system
CN105246194B (zh) 2011-11-15 2018-07-03 昂宝电子（上海）有限公司 用于各种操作模式中的恒流控制的led照明系统和方法
US9807841B2 (en) 2012-07-12 2017-10-31 Hubbell Incorporated Circuit for expanding the dimming range of an LED lamp
KR101690305B1 (ko) 2014-10-16 2016-12-27 주식회사 솔루엠 컨버터
CN104409036B (zh) 2014-12-16 2017-01-11 上海天马微电子有限公司 一种显示面板和显示装置

Also Published As

Publication number Publication date
WO2000009153A1 (en) 2000-02-24
EP1027069B1 (en) 2006-07-26
JP2010031023A (ja) 2010-02-12
IL177228A0 (en) 2006-12-10
US20100041151A1 (en) 2010-02-18
EP1027069A1 (en) 2000-08-16
AU734290B2 (en) 2001-06-07
DE69835367D1 (de) 2006-09-07
US6066626A (en) 2000-05-23
IL135578A (en) 2007-03-08
EP2147681A1 (en) 2010-01-27
CA2305768A1 (en) 2000-02-24
US20030087868A1 (en) 2003-05-08
JP2002522509A (ja) 2002-07-23
AU1284799A (en) 2000-03-06
DE69835367T2 (de) 2007-08-02
ATE333893T1 (de) 2006-08-15
ES2268799T3 (es) 2007-03-16

Similar Documents

Publication Publication Date Title
IL135578A0 (en) Compositions and methods for treating lysosomal storage disease
AU4186199A (en) Method of enhancing lysosomal alpha-galactosidase a
AU655579B2 (en) Anti-pathogenically effective compositions comprising lytic peptides and hydrolytic enzymes
NZ243500A (en) Nucleic acid encoding dihydrokaempferol hydroxylating enzyme (dhk) and its use in producing transgenic flowering plants
CA2120514A1 (en) Synthetic dna sequence having enhanced insecticidal activity in maize
ZA200006594B (en) DSRNA-mediated regulation of gene expression in plants.
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
IL72643A (en) Gene encoding an analog of human interleukin-ii which substantially retains the biological activity of natural human interleukin-ii,microorganism expression vector containing the gene,microorganisms transformed by the vector and the human interleukin-ii analog produced by the microorganisms
EP0914411A4 (en) N-ACYL ETHYLENEDIAMINETRIACETIC ACID SURFACTANTS AS SURFACTANTS, STABILIZERS AND ACTIVATORS COMPATIBLE WITH ENZYMES
GB9009307D0 (en) Dna,constructs,cells and plant derived therefrom
WO2000011946A3 (en) Prolonged storage of red blood cells
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
EP1102528A4 (en) TRANSLATION CONTROL COMPONENTS FOR HIGH-PURITY PROTEIN EXPRESSION IN PLASTERS OF HIGHER PLANTS AND METHOD FOR USE THEREOF
EP0662512A3 (en) Human hematopoietic stem cells.
PL337994A1 (en) Drozomycin coding hybrid gene, vector incorporating same, and method of obtaining transgenic plants resistant to plant diseases
BG105779A (en) Human antibiotic proteins
FR2795424B1 (fr) Promoteur s'exprimant specifiquement dans les cellules de racines de plantes, vecteurs et cellules hotes recombinantes comprenant un tel promoteur et plantes transgeniques obtenues
GB9315751D0 (en) Dna,dna constructs,cells and plants derived therefrom
ZA9810759B (en) Proliferatively active product for treating proliferating cells.
HU890379D0 (en) Agent for land-amelioration
DE69316352D1 (de) Eine methode zur einschränkung des uberlebens gentechnologisch hergestellter mikroorganismen in ihrer umgebung
Takao et al. The material of the species dealt in von Siebold's Flora Japonica Ⅰ
AU7090398A (en) Transgenic non-human animal, tissue, cell cultures and cells derived therefrom, and use thereof
AU7090598A (en) Transgenic non-human animal, tissue, cell cultures, and cells derived therefrom,and use thereof
WO1998035027A3 (en) Human nerve growth factor exon 1 and exon 3 promoters

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed